Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis.
Regner-Nelke L, Pawlitzki M, Willison A, Rolfes L, Oezalp SH, Nelke C, Kölsche T, Korsen M, Grothe M, Groppa S, Luessi F, Engel S, Nelles G, Bonmann E, Roick H, Friedrich A, Knorn P, Landefeld H, Biro Z, Ernst M, Bayas A, Menacher M, Akgün K, Kleinschnitz C, Ruck T, Ziemssen T, Pul R, Meuth SG. Regner-Nelke L, et al. Among authors: korsen m. Neurol Res Pract. 2022 Nov 7;4(1):55. doi: 10.1186/s42466-022-00219-3. Neurol Res Pract. 2022. PMID: 36336685 Free PMC article.
Aggressive spinal cord involvement in granulomatosis with polyangiitis.
Pawlitzki M, Perosa V, Korsen M, Mawrin C, Bartels C, Huchtemann T. Pawlitzki M, et al. Among authors: korsen m. Int J Rheum Dis. 2019 Apr;22(4):756-758. doi: 10.1111/1756-185X.13561. Epub 2019 Apr 4. Int J Rheum Dis. 2019. PMID: 30950232 No abstract available.
Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
Rolfes L, Pfeuffer S, Hackert J, Pawlitzki M, Ruck T, Sondermann W, Korsen M, Wiendl H, Meuth SG, Kleinschnitz C, Pul R. Rolfes L, et al. Among authors: korsen m. Neurol Neuroimmunol Neuroinflamm. 2021 Apr 9;8(3):e990. doi: 10.1212/NXI.0000000000000990. Print 2021 May. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33837059 Free PMC article.
A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab.
Räuber S, Pawlitzki M, Korsen M, Kullmann JS, Thoene D, Pfeuffer S, Rolfes L, Nelke C, Melzer N, Ruck T, Meuth SG; INFUSE-MS study group. Räuber S, et al. Among authors: korsen m. Mult Scler Relat Disord. 2022 Mar;59:103670. doi: 10.1016/j.msard.2022.103670. Epub 2022 Feb 5. Mult Scler Relat Disord. 2022. PMID: 35150978 Free article.
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab.
Räuber S, Korsen M, Huntemann N, Rolfes L, Müntefering T, Dobelmann V, Hermann AM, Kölsche T, von Wnuck Lipinski K, Schroeter CB, Nelke C, Regner-Nelke L, Ingwersen J, Pawlitzki M, Teegen B, Barnett MH, Hartung HP, Aktas O, Albrecht P, Levkau B, Melzer N, Ruck T, Meuth SG, Kremer D. Räuber S, et al. Among authors: korsen m. J Neurol Neurosurg Psychiatry. 2022 Sep;93(9):978-985. doi: 10.1136/jnnp-2021-328197. Epub 2022 Feb 22. J Neurol Neurosurg Psychiatry. 2022. PMID: 35193952 Free PMC article.
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
Räuber S, Willison A, Korsen M, Kölsche T, Golombeck KS, Plaack B, Schüller J, Huntemann N, Rolfes L, Schroeter CB, Nelke C, Regner-Nelke L, Förster M, Ringelstein M, Barnett MH, Hartung HP, Aktas O, Albrecht P, Ruck T, Melzer N, Meuth SG, Kremer D. Räuber S, et al. Among authors: korsen m. Front Immunol. 2022 Dec 23;13:1037214. doi: 10.3389/fimmu.2022.1037214. eCollection 2022. Front Immunol. 2022. PMID: 36618356 Free PMC article.
18 results